Harmony Biosciences Holdings, Inc. (HRMY) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Harmony Biosciences Holdings, Inc. (HRMY) closed at USD 38.27 on 2026-10-15, a change of +30.5 % over the past year, with a market capitalization of USD 2.21B.

Harmony Biosciences Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Harmony Biosciences Holdings, Inc. key figures

Previous close

USD 38.27 (2026-10-15)

1-year change

+30.5 %

Market cap

USD 2.21B

Enterprise value

USD 1.7B

P/E ratio (trailing)

12.24

P/E ratio (forward)

5.42

EPS (trailing)

3.10

EPS (forward)

7.00

PEG ratio

n/a

Price to book

2.21

Revenue growth

30.3 %

Earnings growth

88.2 %

Dividend per share (trailing)

0.00

Short ratio

5.12

Employees

293

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Harmony Biosciences Holdings, Inc. and compare it with other stocks.